Hexstone Capital

Propanc Biopharma (PPCB) secured up to $100 million in financing from Hexstone Capital on Oct 15, 2025. The agreement involves issuing Series C convertible preferred stock and warrants, funding clinical pipeline development and digital asset treasury expansion. Conversion price is $5.00 per share, with $99M potential from warrants. Propanc can call up to $5M preferred monthly. The financing aims to grow Propanc’s treasury to $100 million within 12 months. Potential dilution and ownership limits exist; details in SEC filings.